Makhosazane Zungu-Edmondson1, Nataliia V Shults1, Chi-Ming Wong1, Yuichiro J Suzuki2. 1. Department of Pharmacology and Physiology, Georgetown University Medical Center, 3900 Reservoir Road NW, Washington DC 20057, USA. 2. Department of Pharmacology and Physiology, Georgetown University Medical Center, 3900 Reservoir Road NW, Washington DC 20057, USA ys82@georgetown.edu.
Abstract
AIMS: Right ventricular (RV) failure is the major cause of death among patients with pulmonary arterial hypertension (PAH). However, the mechanism of RV failure has not been defined. METHODS AND RESULTS: This study examined mechanisms and consequences of RV myocyte apoptosis and fibrosis in response to PAH. Rats were injected with SU5416 (vascular endothelial growth factor inhibitor), followed by hypoxia for 3 weeks, and subsequently maintained in normoxia for 2, 5, or 14 weeks (5-, 8-, and 17-week time points after the SU5416 injection, respectively). RV systolic pressure (RVSP) was elevated to >70 mmHg at 5-week time point, and this pressure was sustained thereafter. Significant RV myocyte apoptosis and fibrosis were observed at 8- and 17-week time points. Apoptosis was associated with downregulated Bcl-xL (anti-apoptotic protein), downregulated GATA4 (transcriptional regulator of Bcl-xL), and upregulated p53 (negative regulator of GATA4 gene transcription). PAH-mediated RV apoptosis and fibrosis were attenuated in p53 knock-out rats. Despite the major loss of cardiomyocytes, RV contractility was enhanced, suggesting that the remaining myocytes can perform improved contractile functions. Improved RV contractility is associated with the increased expression of contractile and sarcoplasmic reticulum Ca(2+) uptake proteins. In contrast, the expression of calsequestrin 2 (CSQ2) was downregulated. The siRNA knockdown of CSQ2 improved RV contractility and increased the expression of contractile and Ca(2+) uptake proteins. CONCLUSION: These results suggest that RV decompensation is associated with the death of cardiomyocytes, resulting in fibrosis. However, the remaining myocytes are capable of sustaining RV contractility through the mechanism that involves CSQ2. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Right ventricular (RV) failure is the major cause of death among patients with pulmonary arterial hypertension (PAH). However, the mechanism of RV failure has not been defined. METHODS AND RESULTS: This study examined mechanisms and consequences of RV myocyte apoptosis and fibrosis in response to PAH. Rats were injected with SU5416 (vascular endothelial growth factor inhibitor), followed by hypoxia for 3 weeks, and subsequently maintained in normoxia for 2, 5, or 14 weeks (5-, 8-, and 17-week time points after the SU5416 injection, respectively). RV systolic pressure (RVSP) was elevated to >70 mmHg at 5-week time point, and this pressure was sustained thereafter. Significant RV myocyte apoptosis and fibrosis were observed at 8- and 17-week time points. Apoptosis was associated with downregulated Bcl-xL (anti-apoptotic protein), downregulated GATA4 (transcriptional regulator of Bcl-xL), and upregulated p53 (negative regulator of GATA4 gene transcription). PAH-mediated RV apoptosis and fibrosis were attenuated in p53 knock-out rats. Despite the major loss of cardiomyocytes, RV contractility was enhanced, suggesting that the remaining myocytes can perform improved contractile functions. Improved RV contractility is associated with the increased expression of contractile and sarcoplasmic reticulum Ca(2+) uptake proteins. In contrast, the expression of calsequestrin 2 (CSQ2) was downregulated. The siRNA knockdown of CSQ2 improved RV contractility and increased the expression of contractile and Ca(2+) uptake proteins. CONCLUSION: These results suggest that RV decompensation is associated with the death of cardiomyocytes, resulting in fibrosis. However, the remaining myocytes are capable of sustaining RV contractility through the mechanism that involves CSQ2. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Marie M Budev; Alejandro C Arroliga; Herbert P Wiedemann; Richard A Matthay Journal: Semin Respir Crit Care Med Date: 2003-06 Impact factor: 3.119
Authors: Wihelma Echevarría; M Fatima Leite; Mateus T Guerra; Warren R Zipfel; Michael H Nathanson Journal: Nat Cell Biol Date: 2003-05 Impact factor: 28.824
Authors: Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau Journal: Eur Heart J Date: 2009-08-27 Impact factor: 29.983
Authors: Krishna C Penumatsa; Deniz Toksoz; Rod R Warburton; Mousa Kharnaf; Ioana R Preston; Navin K Kapur; Chaitan Khosla; Nicholas S Hill; Barry L Fanburg Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-08-03 Impact factor: 5.464
Authors: Nataliia V Shults; Sergey S Kanovka; Jennifer E Ten Eyck; Vladyslava Rybka; Yuichiro J Suzuki Journal: J Am Heart Assoc Date: 2019-03-05 Impact factor: 5.501